1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ondrejka SL and His ED: Pathology of
B-cell lymphomas: Diagnosis and biomarker discovery. Cancer Treat
Res. 165:27–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Filella X and Foj L: Prostate cancer
detection and prognosis: From prostate specific antigen (PSA) to
exosomal Biomarkers. Int J Mol Sci. 17:pii: E1784. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Sauzay C, Petit A, Bourgeois AM, Barbare
JC, Chauffert B, Galmiche A and Houessinon A: Alpha-foetoprotein
(AFP): A multi-purpose marker in hepatocellular carcinoma. Clin
Chim Acta. 463:39–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Toth DF, Raderer M, Wadsak W and Karanikas
G: Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin
lymphoma: A comparative study with FDG-PET. Anticancer Res.
33:3341–3345. 2013.PubMed/NCBI
|
6
|
William BM, Bongu NR, Bast M, Bociek RG,
Bierman PJ, Vose JM and Armitage JO: The utility of lactate
dehydrogenase in the follow up of patients with diffuse large
B-cell lymphoma. Rev Bras Hematol Hemoter. 35:189–191.
2013.PubMed/NCBI
|
7
|
Leslie LA, Skarbnik AP, Bejot C, Stives S,
Feldman TA and Goy AH: Targeting indolent non-Hodgkin lymphoma.
Expert Rev Hematol. 10:299–313. 2017. View Article : Google Scholar : PubMed/NCBI
|
8
|
van den Brand M, Scheijen B, Hess CJ, van
Krieken JHJ and Groenen PJTA: Pathways towards indolent B-cell
lymphoma-Etiology and therapeutic strategies. Blood Rev.
31:426–435. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sweetenham JW: Following aggressive B-cell
lymphoma. Blood. 125:3673–3674. 2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Yuen AR, Kamel OW, Halpern J and Horning
SJ: Long-term survival after histologic transformation of low-grade
follicular lymphoma. J Clin Oncol. 13:1726–1733. 1995. View Article : Google Scholar : PubMed/NCBI
|
11
|
Amann A, Costello Bde L, Miekisch W,
Schubert J, Buszewski B, Pleil J, Ratcliffe N and Risby T: The
human volatilome: Volatile organic compounds (VOCs) in exhaled
breath, skin emanations, urine, feces and saliva. J Breath Res.
8:0340012014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Bouatra S, Aziat F, Mandal R, Guo AC,
Wilson MR, Knox C, Bjorndahl TC, Krishnamurthy R, Saleem F, Liu P,
et al: The human urine metabolome. PLoS One. 8:e730762013.
View Article : Google Scholar : PubMed/NCBI
|
13
|
de Lacy Costello B, Amann A, Al-Kateb H,
Flynn C, Filipiak W, Khalid T, Osborne D and Ratcliffe NM: A review
of the volatiles from the healthy human body. J Breath Res.
8:0140012014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Silva CL, Passos M and Camara JS:
Investigation of urinary volatile organic metabolites as potential
cancer biomarkers by solid-phase microextraction in combination
with gas chromatography-mass spectrometry. Br J Cancer.
105:1894–1904. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Guadagni R, Miraglia N, Simonelli A,
Silvestre A, Lamberti M, Feola D, Acampora A and Sannolo N:
Solid-phase microextraction-gas chromatography-mass spectrometry
method validation for the determination of endogenous substances:
Urinary hexanal and heptanal as lung tumor biomarkers. Anal Chim
Acta. 701:29–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the Committee on Hodgkin's
Disease Staging Classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
17
|
Banday KM, Pasikanti KK, Chan EC, Singla
R, Rao KV, Chauhan VS and Nanda RK: Use of urine volatile organic
compounds to discriminate tuberculosis patients from healthy
subjects. Anal Chem. 83:5526–5534. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Mills GA and Walker V: Headspace
solid-phase microextraction profiling of volatile compounds in
urine: Application to metabolic investigations. Journal of
chromatography. J Chromatogr B Biomed Sci Appl. 753:259–268. 2001.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Qin T, Liu H, Song Q, Song G, Wang HZ, Pan
YY, Xiong FX, Gu KS, Sun GP and Chen ZD: The screening of volatile
markers for hepatocellular carcinoma. Cancer Epidemiol Biomarkers
Prev. 19:2247–2253. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Song G, Qin T, Liu H, Xu GB, Pan YY, Xiong
FX, Gu KS, Sun GP and Chen ZD: Quantitative breath analysis of
volatile organic compounds of lung cancer patients. Lung Cancer.
67:227–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ansell SM: Non-Hodgkin Lymphoma: Diagnosis
and Treatment. Mayo Clin Proc. 90:1152–1163. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Kumar A, Sundararajan S, Puvvada S and
Persky DO: Limited stage aggressive non-hodgkin lymphoma: What is
optimal therapy? Curr Treat Options Oncol. 17:452016. View Article : Google Scholar : PubMed/NCBI
|
23
|
Filippi AR, Ciammella P and Ricardi U:
Limited stage follicular lymphoma: Current role of radiation
therapy. Mediterr J Hematol Infect Dis. 8:e20160412016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gine E and Sehn LH: Diffuse large B-cell
lymphoma: Should limited-stage patients Be treated differently?
Hematol Oncol Clin North Am. 30:1179–1194. 2016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Till BG, Li H, Bernstein SH, Fisher RI,
Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr,
Pozdnyakova O, et al: Phase II trial of R-CHOP plus bortezomib
induction therapy followed by bortezomib maintenance for newly
diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol.
172:208–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Phan J, Mazloom A, Medeiros LJ, Zreik TG,
Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, et
al: Benefit of consolidative radiation therapy in patients with
diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J
Clin Oncol. 28:4170–4176. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Montoto S, Davies AJ, Matthews J,
Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner
AZ and Lister TA: Risk and clinical implications of transformation
of follicular lymphoma to diffuse large B-cell lymphoma. J Clin
Oncol. 25:2426–2433. 2007. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chan JK and Kwong YL: Common misdiagnoses
in lymphomas and avoidance strategies. Lancet Oncol. 11:579–588.
2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ramos AG, Anton AP, Sanchez MDN, Pavon JLP
and Cordero BM: Urinary volatile fingerprint based on mass
spectrometry for the discrimination of patients with lung cancer
and controls. Talanta. 174:158–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
30
|
Shestivska V, Rutter AV, Sulé-Suso J,
Smith D and Španěl P: Evaluation of peroxidative stress of cancer
cells in vitro by real-time quantification of volatile aldehydes in
culture headspace. Rapid Commun Mass Spectrom. 31:1344–1352. 2017.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Anton Perez A, Ramos AG, Del Nogal Sanchez
M, Pavon JL, Cordero BM and Pozas AP: Headspace-programmed
temperature vaporization-mass spectrometry for the rapid
determination of possible volatile biomarkers of lung cancer in
urine. Anal Bioanal Chem. 408:5239–5246. 2016. View Article : Google Scholar : PubMed/NCBI
|
32
|
Rios-Arrabal S, Artacho-Cordon F, Leon J,
Román-Marinetto E, Del Mar Salinas-Asensio M, Calvente I and Núñez
MI: Involvement of free radicals in breast cancer. Springer Plus.
2:4042013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Walker V and Mills GA: Urine 4-heptanone:
A beta-oxidation product of 2-ethylhexanoic acid from plasticisers.
Clin Chim Acta. 306:51–61. 2001. View Article : Google Scholar : PubMed/NCBI
|
34
|
Karami S, Boffetta P, Brennan P, Stewart
PA, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V,
Navratilova M, et al: Renal cancer risk and occupational exposure
to polycyclic aromatic hydrocarbons and plastics. J Occup Environ
Med. 53:218–223. 2011. View Article : Google Scholar : PubMed/NCBI
|
35
|
Hanai Y, Shimono K, Oka H, Baba Y,
Yamazaki K and Beauchamp GK: Analysis of volatile organic compounds
released from human lung cancer cells and from the urine of
tumor-bearing mice. Cancer Cell Int. 12:72012. View Article : Google Scholar : PubMed/NCBI
|
36
|
Calejo I, Moreira N, Araujo AM, Carvalho
M, Bastos Mde L and de Pinho PG: Optimisation and validation of a
HS-SPME-GC-IT/MS method for analysis of carbonyl volatile compounds
as biomarkers in human urine: Application in a pilot study to
discriminate individuals with smoking habits. Talanta. 148:486–493.
2016. View Article : Google Scholar : PubMed/NCBI
|
37
|
Krupenko SA and Oleinik NV:
10-formyltetrahydrofolate dehydrogenase, one of the major folate
enzymes, is down-regulated in tumor tissues and possesses
suppressor effects on cancer cells. Cell Growth Differ. 13:227–236.
2002.PubMed/NCBI
|
38
|
Ma S, Chan KW, Lee TK, Tang KH, Wo JY,
Zheng BJ and Guan XY: Aldehyde dehydrogenase discriminates the
CD133 liver cancer stem cell populations. Mol Cancer Res.
6:1146–1153. 2008. View Article : Google Scholar : PubMed/NCBI
|
39
|
Khalid T, Aggio R, White P, De Lacy
Costello B, Persad R, Al-Kateb H, Jones P, Probert CS and Ratcliffe
N: Urinary Volatile Organic Compounds for the Detection of Prostate
Cancer. PLoS One. 10:e01432832015. View Article : Google Scholar : PubMed/NCBI
|
40
|
Hughes SD, Kanabus M, Anderson G,
Hargreaves IP, Rutherford T, O'Donnell M, Cross JH, Rahman S, Eaton
S and Heales SJ: The ketogenic diet component decanoic acid
increases mitochondrial citrate synthase and complex I activity in
neuronal cells. J Neurochem. 129:426–433. 2014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Malapaka RR, Khoo S, Zhang J, Choi JH,
Zhou XE, Xu Y, Gong Y, Li J, Yong EL, Chalmers MJ, et al:
Identification and mechanism of 10-carbon fatty acid as modulating
ligand of peroxisome proliferator-activated receptors. J Biol Chem.
287:183–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
42
|
Mazzone PJ, Wang XF, Lim S, Choi H, Jett
J, Vachani A, Zhang Q, Beukemann M, Seeley M, Martino R and Rhodes
P: Accuracy of volatile urine biomarkers for the detection and
characterization of lung cancer. BMC Cancer. 15:10012015.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Gasparri R, Santonico M, Valentini C,
Sedda G, Borri A, Petrella F, Maisonneuve P, Pennazza G, D'Amico A,
Di Natale C, et al: Volatile signature for the early diagnosis of
lung cancer. J Breath Res. 10:0160072016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Handa H, Usuba A, Maddula S, Baumbach JI,
Mineshita M and Miyazawa T: Exhaled breath analysis for lung cancer
detection using ion mobility spectrometry. PLoS One. 9:e1145552014.
View Article : Google Scholar : PubMed/NCBI
|